Spinal Cord Research Help
AboutCategoriesLatest ResearchContact
Subscribe
Spinal Cord Research Help

Making Spinal Cord Injury (SCI) Research Accessible to Everyone. Simplified summaries of the latest research, designed for patients, caregivers and anybody who's interested.

Quick Links

  • Home
  • About
  • Categories
  • Latest Research
  • Disclaimer

Contact

  • Contact Us
© 2025 Spinal Cord Research Help

All rights reserved.

  1. Home
  2. Research
  3. Spinal Cord Injury
  4. The nociceptin receptor inhibits axonal regeneration and recovery from spinal cord injury

The nociceptin receptor inhibits axonal regeneration and recovery from spinal cord injury

Sci Signal, 2018 · DOI: 10.1126/scisignal.aao4180 · Published: April 3, 2018

Spinal Cord InjuryRegenerative MedicineNeurology

Simple Explanation

After spinal cord injury, the interruption of axonal tracts leads to disconnection of neurons and loss of function. This study showed that nociceptin/ ORL1 signaling limits neural repair. Treatment with an ORL1 antagonist in a clinically relevant time window enhanced neural repair and recovery of mice after SCI.

Study Duration
56-98 days
Participants
WT and Ngr1−/− mice
Evidence Level
Not specified

Key Findings

  • 1
    ORL1 expression promoted glycosylation and surface expression of NgR1 to mediate inhibition of axonal regeneration by myelin-associated inhibitors.
  • 2
    Nociceptin/ORL1 signaling through the RhoA/ROCK pathway inhibited axonal regeneration independently of NgR1.
  • 3
    Administration of the ORL1 antagonist J113397 after hemisection SCI in WT mice increased raphespinal axon sprouting caudal to injury site.

Research Summary

This study showed that nociceptin/ ORL1 signaling limits neural repair. ORL1 expression promoted glycosylation and surface expression of NgR1 to mediate inhibition of axonal regeneration by myelin-associated inhibitors. Treatment with an ORL1 antagonist in a clinically relevant time window enhanced neural repair and recovery of mice after SCI.

Practical Implications

Therapeutic Target

ORL1 is a potential therapeutic target for promoting neural repair after spinal cord injury.

Drug Development

ORL1 antagonists could be developed as drugs to enhance recovery from traumatic CNS injuries.

Combination Therapy

Combining ORL1 antagonism with Nogo receptor inhibition may lead to greater functional recovery after SCI.

Study Limitations

  • 1
    The mechanism of increased ORL1 transcriptional regulation is not defined here
  • 2
    Whether the ORL1 gene is induced only by SCI in combination with Ngr1 deficiency is not clear.
  • 3
    it is likely that J113397 improves treatment by affecting multiple pathways, and no single pathway is the proximate cause for functional improvements.

Your Feedback

Was this summary helpful?

Back to Spinal Cord Injury